Cystic Fibrosis in Southern Iran

Karjoo, Manouchehr; Bahremand, Manidjeh; Mihandoust, Gholamhosein

doi:10.1093/tropej/30.4.195

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…performed pilocarpine iontophoresis on 125 suspected patients and twenty controls from Fars Province in Southern Iran. Only three patients were found to have CF on the basis of the clinical findings, repeated elevations of sweat chloride levels, and evidence of pancreatic insufficiency,[19] but the present study suggests that the occurrence of CF in Iran is higher in high-risk children than previously thought. In our study, CF was diagnosed in 17.6% of high-risk children.…”

Section: Discussioncontrasting

confidence: 51%

See 1 more Smart Citation

Cystic fibrosis prevalence among a group of high-risk children in the main referral children hospital in Iran

Modaresi

Faghinia

Reisi

et al. 2017

J Edu Health Promot

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 51%

“…Few reports have been published about CF patients in the Middle East. [181920] These reports indicated frequencies ranging from 1:5800 in Bahrain[13] to 1:2650 in Jordan. [21] Naguib et al .…”

Section: Discussionmentioning

confidence: 99%

Cystic fibrosis prevalence among a group of high-risk children in the main referral children hospital in Iran

Modaresi

Faghinia

Reisi

et al. 2017

J Edu Health Promot

View full text Add to dashboard Cite

“…However there are a few papers reporting different statistics of CF in different regions of Iran. For instance, while no confirmed case of CF has been reported in southern Iran ( 5 ), there is a report from north-west of Iran on CF prevalence of 7.98 in 100 thousand during the 5-year period (2004-2008)( 6 ) in addition to a study reported growth pattern and nutritional intake of 34 infants with CF in East Azerbaijan province ( 7 ). Moreover, spectrum of CFTR gene mutations in 200 Iranian Azeri Turkish Patients with Cystic Fibrosis has been examined and reported in another study ( 8 ).…”

Section: Introductionmentioning

confidence: 99%

Minimum Data Set for Cystic Fibrosis Registry: a Case Study in Iran

Kalankesh¹,

Dastgiri²,

Rafeey³

et al. 2015

Acta Inform Med

View full text Add to dashboard Cite

Background:over the last 25 years several national registries of CF have been set up. Such systems can be very useful in providing an integrated resource for improving patient care and conducting research on the disease. Minimum Data Set is a common set of data items that should be used to collect and report data in the registry. The principal aim of this research was to determine minimum data set for the CF registry in north-west of Iran.Methods:data items collected by several selected registries of cystic fibrosis were studied and an initial set of data was selected by the researchers. A group of experts including epidemiologists, pediatricians, and CF specialists were asked to review the proposed data elements and score them based on their importance by using a nine-point Likert scale. The items scored as important or highly important by more than 50 % of the experts, were included in final list of minimum data set. Availability of data was evaluated through reviewing medical records of 144 patients hospitalized in Children Hospital located in Tabriz.Results:overall six classes of data (46 items) were identified in the selected registry systems for cystic fibrosis: patient demographics, administrative data, survival status, diagnostic procedures, genetic and clinical manifestations, and therapeutics. Thirty two data elements from all six categories of data were approved by the experts as the minimum data set for cystic fibrosis registry system. Availability of data in administrative category and survival class was 100 percent. Collecting data on medications was feasible in 100% of the cases as well. In class of demographic data, accessibility of patient name, age, gender, place of birth, and date of birth was 100 percent. In group of diagnostic procedures, partial availability of data was found for sweat test and genetic test. No data was found on the antenatal screening, exercise tolerance test, and glucose tolerance test.Conclusion:this work can be considered as a first step toward establishing CF registry system in Iran. Minimum data set can be also useful in designing electronic registry or electronic patient records for those suffering from CF toward integration of their fragmented records across continuum of the health care system in order to improve quality of shared patient care.

show abstract

“…Various incidence rates of CF have been reported in Iran. Some studies have reported no confirmed case of CF in southern Iran [ 16 ], while, according to another report, in the northwest of Iran 7.98 out of 100,000 people suffered CF during a four-year period ranging from 2004 to 2008 [ 17 ]. Considering the high burden of respiratory diseases on governments and individuals including disability, premature deaths, loss in productivity and treatment expenses, medicine affordability in the disease treatments is a crucial issue, particularly in low-resource settings.…”

Section: Introductionmentioning

confidence: 99%

Evaluating the affordability of asthma, chronic obstructive pulmonary disease, and cystic fibrosis medicines in a middle-income country

Fathi,

Moradi,

Yousefi

et al. 2023

BMC Pulm Med

View full text Add to dashboard Cite

Background A heavy financial burden is imposed on patients suffering from chronic diseases due to medicine out-of-pocket payments. Objectives This study focuses on assessing the affordability of medications used for chronic respiratory diseases (CRDs) such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF) in Iran, specifically on the category R medicines listed in the 2017 Iran drug list (IDL) that are used for the treatment of these diseases, based on the anatomical therapeutic chemical (ATC) drug code. Methods The affordability of medicines in mono and combination therapy approaches was assessed in CRDs using the World Health Organization/Health Action International (WHO/HAI) methodology. Accordingly, if out-of-pocket payment for 30-days of pharmacotherapy exceeds one day for the lowest-paid unskilled government worker (LPGW), it’s considered non-affordable. Results Based on the monotherapy approach, our finding demonstrates that all generic medicines of category R were affordable. However, branded drugs such as Symbicort®, Pulmicort Respules®, Flusalmex®, Seretide®, Fluticort Plus®, Seroflo®, and Salmeflo® cost between 1.2 and 2.5 days’ wage of LPGW and considered unaffordable despite 70% insurance coverage. Moreover, based on the affordability ratio in the combination therapy approach, all medicines used in asthma, COPD, and CF patients with mild respiratory problems are affordable except omalizumab (inj), which is non-affordable due to its high price and no insurance coverage. Conclusion Results showed that the existing insurance coverage does not protect households from hardship, so more considerations are needed such as different insurance schedules and patient support programs.

show abstract

Cystic Fibrosis in Southern Iran

Cited by 4 publications

References 0 publications

Cystic fibrosis prevalence among a group of high-risk children in the main referral children hospital in Iran

Cystic fibrosis prevalence among a group of high-risk children in the main referral children hospital in Iran

Minimum Data Set for Cystic Fibrosis Registry: a Case Study in Iran

Evaluating the affordability of asthma, chronic obstructive pulmonary disease, and cystic fibrosis medicines in a middle-income country

Contact Info

Product

Resources

About